MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma (SCC)

Genomic analyses of SCC have yet to yield significant strategies against pathway activation to improve treatment. Platinum-based chemotherapy remains the mainstay of treatment for SCC of different histotypes either as a single agent or alongside other chemotherapeutic drugs or radiotherapy; however, resistance inevitably emerges, which limits the duration of treatment response. To elucidate mechanisms that mediate resistance to cisplatin, we compared drug-induced perturbations to gene expression between cisplatin-sensitive and -resistant SCC cells.

Dataset features

Information

Specifications

Application:	Gene expression microarray analysis
Number of samples:	32
Release date:	Aug 5 2015
Last update date:	Jul 26 2018
Access:	Public
Diseases:	Carcinoma
Chemicals:	Cisplatin
Dataset link	MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma (SCC)

Experimental Protocol

Cisplatin-sensitive and -resistant SCC cells were identified through MTS assay. Gene expression profiling (Affymetrix GeneChip 1.0ST) was performed to identify putative genes and cellular pathways that may be associated with cellular response to cisplatin.

Repositories

GEO

GSE66549

ArrayExpress

E-GEOD-66549

BioProject

PRJNA277308

Download

Contact

Chong-Lei Bi